Unbiased AI-powered news
The Environmental Protection Agency announced plans to rescind limits on four PFAS substances and extend compliance deadlines for two others. Officials cited implementation challenges and legal risks with the prior rules.
The Environmental Protection Agency announced plans to rescind limits on four PFAS substances in drinking water and extend compliance deadlines for two others. Officials described the move as addressing timelines that water systems could not meet. The changes target rules approved in 2024.
Extended exposure to PFAS has been linked to cancers and other health effects. The substances appear in tap water in some congressional districts and in the blood of most Americans.
Proposed regulatory adjustments Restrictions on four PFAS substances would be removed entirely. Water utilities would receive two additional years to meet limits for the remaining two substances. The agency said the prior deadlines risked violations without reducing contamination levels.
Officials pointed to ongoing lawsuits from water utilities and chemical companies. The EPA stopped defending the standards in court after seeking to vacate four restrictions last fall. A 60-day public comment period will precede finalization of the changes.
Funding for detection and removal The administration highlighted $1 billion in grant funding for small and disadvantaged communities to detect and remove PFAS. The funding stems from a congressional appropriation made in 2021. Officials said the grants represent a financial commitment to address the chemicals.
An attorney for the Natural Resources Defense Council said the agency appears to have adopted positions from industry challengers. A dean emeritus at New York University School of Law stated that legal challenges are likely because the Safe Drinking Water Act restricts weakening existing standards.
Single source — no framing comparison available.
BBC NewsNovo Nordisk filed a lawsuit Tuesday in U.S. District Court in New Jersey alleging Eli Lilly ran false and misleading ads for its GLP-1 medicines. The complaint targets comparisons that pit higher doses of Lilly drugs against lower doses of Novo Nordisk products.
msnbc.comBiotech firms are pressing the White House to exclude treatments for rare diseases from two Medicare pilot programs that lower brand drug prices. The Rare Disease Company Coalition met last week with the Office of Management and Budget to discuss the request.
The IndependentJenitar Na'amoana, 34, gave birth to four monozygotic girls by caesarean section on July 14 at Royal Brisbane and Women’s Hospital. The infants, born at 28 weeks and four days, share a single placenta and remain in neonatal intensive care.